More about

Ipilimumab

News
July 12, 2021
3 min read
Save

Immunotherapy combination shows antitumor activity in PD-1-refractory melanoma

Immunotherapy combination shows antitumor activity in PD-1-refractory melanoma

The combination of pembrolizumab and low-dose ipilimumab appeared tolerable and led to significant antitumor activity among patients with advanced melanoma who previously failed prior immunotherapy, according to phase 2 study results.

News
June 25, 2021
1 min read
Save

Checkmate9LA demonstrates benefit of combination therapy in advanced NSCLC

A 2-year update on Checkmate9LA suggested that combining nivolumab with ipilimumab and two cycles of chemoradiation may be better than four cycles of chemoradiation alone, according to a speaker at the virtual 2021 ASCO Annual Meeting.

News
June 03, 2021
2 min read
Save

Two nivolumab regimens outperform chemotherapy alone in advanced esophageal cancer

Two nivolumab regimens outperform chemotherapy alone in advanced esophageal cancer

The addition of nivolumab to chemotherapy or ipilimumab significantly improved OS compared with chemotherapy alone among patients with previously untreated advanced esophageal squamous cell carcinoma, according to phase 3 study findings.

News
April 14, 2021
3 min read
Save

Nivolumab-ipilimumab combination demonstrates antitumor activity in prostate cancer subset

Nivolumab-ipilimumab combination demonstrates antitumor activity in prostate cancer subset

A combination of nivolumab and ipilimumab induced significant antitumor activity among men with metastatic castration-resistant prostate cancer and a positive immunogenic signature, according to results of the phase 2 NEPTUNES trial.

News
April 12, 2021
1 min read
Save

Opdivo demonstrates positive results in patients with upper GI cancers

Bristol Myers Squibb announced positive results from its phase 3 CheckMate-648 trial of nivolumab for the treatment of patients with unresectable advanced or metastatic esophageal squamous cell carcinoma.

News
March 20, 2021
3 min read
Save

Neoadjuvant combination immunotherapy ‘promising’ for early-stage NSCLC

Neoadjuvant combination immunotherapy ‘promising’ for early-stage NSCLC

Neoadjuvant combination immunotherapy improved outcomes for patients with operable non-small cell lung cancer, according to results of the randomized phase 2 NEOSTAR trial.

News
February 02, 2021
3 min read
Save

Addition of ipilimumab to pembrolizumab fails to improve outcomes for NSCLC subset

Addition of ipilimumab to pembrolizumab fails to improve outcomes for NSCLC subset

The addition of first-line ipilimumab to pembrolizumab did not improve outcomes for patients with metastatic non-small cell lung cancer who had PD-L1 tumor proportion scores of 50% or greater and no targetable EGFR or ALK aberrations.

News
January 28, 2021
1 min read
Save

Top in hem/onc: Updates in colorectal cancer

Top in hem/onc: Updates in colorectal cancer

A recent study presented at the Gastrointestinal Cancers Symposium revealed low health-related quality of life scores among young adult survivors of colorectal cancer. It was the top story in hematology/oncology last week.

News
January 13, 2021
2 min read
Save

Healio round-up: 2020 game changing lung cancer trials

2020 presented many challenges, including the transformation of conferences and meetings into virtual events.

News
December 11, 2020
11 min watch
Save

VIDEO: Decitabine plus ipilimumab shows ‘promising clinical activity’ in AML

VIDEO: Decitabine plus ipilimumab shows ‘promising clinical activity’ in AML

In patients with relapsed or refractory or secondary acute myeloid leukemia/myelodysplastic syndromes, decitabine plus ipilimumab had an expected adverse event profile and showed encouraging clinical activity, according to an ongoing phase 1 study.

View more